# Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy

Study · id `cardio:ct-nct02068443` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02068443](<https://clinicaltrials.gov/study/NCT02068443>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02068443

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 374 participants.

## Technical summary

Registry record NCT02068443. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-06-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 374 participants (enrolled count; ClinicalTrials.gov record NCT02068443, source copy `cardio:ctgov-nct02068443-2023-09-28`, retrieved 2026-10-26)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT02068443, source copy `cardio:ctgov-nct02068443-2023-09-28`, retrieved 2026-10-26)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02068443, source copy `cardio:ctgov-nct02068443-2023-09-28`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02068443, source copy `cardio:ctgov-nct02068443-2023-09-28`, retrieved 2026-10-26)
- Results first posted: 2016-06-06 (ClinicalTrials.gov record NCT02068443, source copy `cardio:ctgov-nct02068443-2023-09-28`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02068443, source copy `cardio:ctgov-nct02068443-2023-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02068443-2023-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Alogliptin
- Intervention (Drug): Metformin hydrochloride
- Intervention (Drug): Metformin hydrochloride Placebo
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: 99162ebd3b365757b1f642ab0c267035120bfd2aab77e0a23e65b9e21f7bdaa9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
